 | • レポートコード：MRC2211A124 • 出版社/出版日：Transparency Market Research / 2022年8月 • レポート形態：英文、PDF、212ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トレンスペアレンシーマーケットリサーチ社の当調査レポートでは、世界の緑膿菌感染症治療市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、投薬方法別（単剤療法、併用療法）分析、薬剤種類別（アミノグリコシド、セファロスポリン、カルバペネム、モノバクタム、その他）分析、投与経路別（鼻腔、経口、静脈内）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を掲載しています。なお、当書には、ALLERGAN、Teva Pharmaceutical Industries Ltd.、Pfizer Inc.、Lupin Pharmaceuticals, Inc.、AstraZeneca、Merck & Co., Inc.、Bristol-Myers Squibb Co.、Janssen Pharmaceuticals, Inc.などの企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の緑膿菌感染症治療市場規模：投薬方法別 - 単剤療法の市場規模 - 併用療法の市場規模 ・世界の緑膿菌感染症治療市場規模：薬剤種類別 - アミノグリコシドの市場規模 - セファロスポリンの市場規模 - カルバペネムの市場規模 - モノバクタムの市場規模 - その他薬剤の市場規模 ・世界の緑膿菌感染症治療市場規模：投与経路別 - 経鼻投与の市場規模 - 経口投与の市場規模 - 静脈内投与の市場規模 ・世界の緑膿菌感染症治療市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界の緑膿菌感染症治療市場規模：地域別 - 北米の緑膿菌感染症治療市場規模 - ヨーロッパの緑膿菌感染症治療市場規模 - アジア太平洋の緑膿菌感染症治療市場規模 - 中南米の緑膿菌感染症治療市場規模 - 中東・アフリカの緑膿菌感染症治療市場規模 ・競争状況 |
Pseudomonas Aeruginosa Infection Treatment Market – Scope of Report
TMR’s report on the global pseudomonas aeruginosa infection treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global pseudomonas aeruginosa infection treatment market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pseudomonas aeruginosa infection treatment market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the pseudomonas aeruginosa infection treatment market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pseudomonas aeruginosa infection treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global pseudomonas aeruginosa infection treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pseudomonas aeruginosa infection treatment market.
The report delves into the competitive landscape of the global pseudomonas aeruginosa infection treatment market. Key players operating in the global pseudomonas aeruginosa infection treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global pseudomonas aeruginosa infection treatment market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market pseudomonas aeruginosa infection treatment.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Pseudomonas Aeruginosa Infection Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Medication Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecasts, 2017 – 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Diseases Epidemiology
5.2. Pricing Analysis
5.3. Regulatory Scenario
5.4. Reimbursement Scenario by Region/globally
5.5. COVID-19 Impact Analysis
6. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Medication Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Medication Type, 2017 – 2031
6.3.1. Monotherapy
6.3.2. Combination Therapy
6.4. Market Attractiveness, by Medication Type
7. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Drug Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug Type, 2017 – 2031
7.3.1. Aminoglycoside
7.3.2. Cephalosporin
7.3.3. Carbapenem
7.3.4. Monobactam
7.3.5. Others
7.4. Market Attractiveness, by Drug Type
8. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017 – 2031
8.3.1. Nasal
8.3.2. Oral
8.3.3. Intravenous
8.4. Market Attractiveness, by Route of Administration
9. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017 – 2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Country/Region
11. North America Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Medication Type, 2017 – 2031
11.2.1. Monotherapy
11.2.2. Combination Therapy
11.3. Market Value Forecast, by Drug Type, 2017 – 2031
11.3.1. Aminoglycoside
11.3.2. Cephalosporin
11.3.3. Carbapenem
11.3.4. Monobactam
11.3.5. Others
11.4. Market Value Forecast, by Route of Administration, 2017 – 2031
11.4.1. Nasal
11.4.2. Oral
11.4.3. Intravenous
11.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2017 – 2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Medication Type
11.7.2. By Drug Type
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Medication Type, 2017 – 2031
12.2.1. Monotherapy
12.2.2. Combination Therapy
12.3. Market Value Forecast, by Drug Type, 2017 – 2031
12.3.1. Aminoglycoside
12.3.2. Cephalosporin
12.3.3. Carbapenem
12.3.4. Monobactam
12.3.5. Others
12.4. Market Value Forecast, by Route of Administration, 2017 – 2031
12.4.1. Nasal
12.4.2. Oral
12.4.3. Intravenous
12.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country, 2017 – 2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Medication Type
12.7.2. By Drug Type
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Medication Type, 2017 – 2031
13.2.1. Monotherapy
13.2.2. Combination Therapy
13.3. Market Value Forecast, by Drug Type, 2017 – 2031
13.3.1. Aminoglycoside
13.3.2. Cephalosporin
13.3.3. Carbapenem
13.3.4. Monobactam
13.3.5. Others
13.4. Market Value Forecast, by Route of Administration, 2017 – 2031
13.4.1. Nasal
13.4.2. Oral
13.4.3. Intravenous
13.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country, 2017 – 2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Medication Type
13.7.2. By Drug Type
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Medication Type, 2017 – 2031
14.2.1. Monotherapy
14.2.2. Combination Therapy
14.3. Market Value Forecast, by Drug Type, 2017 – 2031
14.3.1. Aminoglycoside
14.3.2. Cephalosporin
14.3.3. Carbapenem
14.3.4. Monobactam
14.3.5. Others
14.4. Market Value Forecast, by Route of Administration, 2017 – 2031
14.4.1. Nasal
14.4.2. Oral
14.4.3. Intravenous
14.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country, 2017 – 2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Medication Type
14.7.2. By Drug Type
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Medication Type, 2017 – 2031
15.2.1. Monotherapy
15.2.2. Combination Therapy
15.3. Market Value Forecast, by Drug Type, 2017 – 2031
15.3.1. Aminoglycoside
15.3.2. Cephalosporin
15.3.3. Carbapenem
15.3.4. Monobactam
15.3.5. Others
15.4. Market Value Forecast, by Route of Administration, 2017 – 2031
15.4.1. Nasal
15.4.2. Oral
15.4.3. Intravenous
15.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country, 2017 – 2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Medication Type
15.7.2. By Drug Type
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Company Profiles
16.2.1. ALLERGAN
16.2.1.1. Company Description
16.2.1.2. Business Overview
16.2.1.3. Financial Overview
16.2.1.4. Strategic Overview
16.2.1.5. SWOT Analysis
16.2.2. Teva Pharmaceutical Industries Ltd.
16.2.2.1. Company Description
16.2.2.2. Business Overview
16.2.2.3. Financial Overview
16.2.2.4. Strategic Overview
16.2.2.5. SWOT Analysis
16.2.3. Pfizer Inc.
16.2.3.1. Company Description
16.2.3.2. Business Overview
16.2.3.3. Financial Overview
16.2.3.4. Strategic Overview
16.2.3.5. SWOT Analysis
16.2.4. Lupin Pharmaceuticals, Inc.
16.2.4.1. Company Description
16.2.4.2. Business Overview
16.2.4.3. Financial Overview
16.2.4.4. Strategic Overview
16.2.4.5. SWOT Analysis
16.2.5. AstraZeneca
16.2.5.1. Company Description
16.2.5.2. Business Overview
16.2.5.3. Financial Overview
16.2.5.4. Strategic Overview
16.2.5.5. SWOT Analysis
16.2.6. Merck & Co., Inc.
16.2.6.1. Company Description
16.2.6.2. Business Overview
16.2.6.3. Financial Overview
16.2.6.4. Strategic Overview
16.2.6.5. SWOT Analysis
16.2.7. Bristol-Myers Squibb Co.
16.2.7.1. Company Description
16.2.7.2. Business Overview
16.2.7.3. Financial Overview
16.2.7.4. Strategic Overview
16.2.7.5. SWOT Analysis
16.2.8. Janssen Pharmaceuticals, Inc.
16.2.8.1. Company Description
16.2.8.2. Business Overview
16.2.8.3. Financial Overview
16.2.8.4. Strategic Overview
16.2.8.5. SWOT Analysis
Table 01: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031
Table 02: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 03: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 04: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031
Table 05: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031
Table 08: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 09: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 10: North America Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 11: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031
Table 13: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 14: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 15: Europe Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031
Table 18: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 19: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 20: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031
Table 23: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 24: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 25: Latin America Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 26: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031
Table 28: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 29: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 30: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031